Company Overview and News

 
Peninsula Energy's US$50 per pound uranium sales contracts to 2030 generate cash while low pH operations gain approval

2018-04-24 proactiveinvestors.com.au
Peninsula Energy Ltd (ASX:PEN) is hitting its straps with the uranium producer exceeding the top end of production guidance of 40,000 pounds at its Lance project in the March quarter.
Upvote Downvote

 
Peninsula Energy receives confirmation of finance as it progresses low pH uranium production

2018-04-22 proactiveinvestors.com.au
Peninsula Energy Ltd (ASX:PEN) has entered into binding offer letters with major shareholders Resource Capital Fund VI L.P. (RCF VI) and Pala Investments Ltd.
Upvote Downvote

 
Peninsula Energy enters ASX trading halt

2018-04-20 proactiveinvestors.com.au
The company requested its shares be halted pending the release of information regarding an extension and restructuring of the existing convertible note facility.
Upvote Downvote

 
Peninsula Energy takes key step forward in transition to low pH uranium operations

2018-04-09 proactiveinvestors.com.au
Peninsula Energy Ltd (ASX:PEN) has submitted a request to the Wyoming Department of Environmental Quality (WDEQ) to allow the use of a low-pH recovery solution in the Ross Permit Area of its Lance Projects in Wyoming, US.
Upvote Downvote

 
Peninsula Energy exceeds uranium production guidance at Lance project, shares up

2018-04-06 proactiveinvestors.com.au
Peninsula Energy Ltd (ASX:PEN) produced 43,638 pounds of uranium from its Wyoming-based Lance Project during the three months to March 31, 2018.
Upvote Downvote

 
Peninsula Energy exceeds uranium production guidance at Lance project

2018-04-06 proactiveinvestors.com.au
Peninsula Energy Ltd (ASX:PEN) produced 43,638 pounds of uranium from its Wyoming-based Lance Project during the three months to March 31, 2018.
Upvote Downvote

 
Peninsula Energy on track for transition to low pH uranium operations at Lance Projects

2018-03-28 proactiveinvestors.com.au
Peninsula Energy Ltd (ASX:PEN) is on track with its transition to low pH uranium operations at the Lance Projects in the US state of Wyoming.
Upvote Downvote

 
PENINSULA ENERGY LTD NEW 2017 Q4 - Results - Earnings Call Slides

2018-02-06 seekingalpha
The following slide deck was published by PENINSULA ENERGY LTD NEW in conjunction with their 2017 Q4 earnings call.
Upvote Downvote

1
Peninsula Energy receives further investment from Global X uranium ETF

2018-02-04 proactiveinvestors.com.au
Peninsula Energy Ltd (ASX:PEN) has had major shareholder, Global X Management Company, increase its stake in the company.
Upvote Downvote

 
Peninsula Energy has buy recommendation reiterated, price target of $1.50

2018-02-02 proactiveinvestors.com.au
Peninsula Energy Ltd (ASX:PEN) has had its buy recommendation reiterated by New York based investment bank H.C. Wainwright & Co.
Upvote Downvote

 
Peninsula sells contract for $US19m

2018-02-01 businessnews.com.au
Peninsula Energy has signed an agreement to sell a portion of its interests in an existing long-term uranium sale and purchase deal for $US19 million ($23.7 million).
Upvote Downvote

 
Peninsula Energy lifts cash position with US$19 million uranium sales deal

2018-02-01 proactiveinvestors.com.au
Peninsula Energy Ltd (ASX:PEN) has strengthened its cash position by selling part of its interests in long-term uranium sale and purchase agreements for US$19 million.
Upvote Downvote

 
Peninsula Energy enters trading halt pending changes to uranium agreements

2018-01-30 proactiveinvestors.com.au
Peninsula Energy Ltd (ASX:PEN) has been granted a trading halt by the ASX pending changes to Peninsula's uranium concentrate sale and purchase agreements.
Upvote Downvote

 
Peninsula Energy lifts uranium production for third straight quarter

2018-01-14 proactiveinvestors.com.au
Peninsula Energy Ltd (ASX:PEN) has achieved its third successive quarter of increased uranium production from the Lance Projects in the U.S.
Upvote Downvote

 
Australia has 'missed the boat' on nuclear power

2018-01-11 theage.com.au
The Minerals Council of Australia has called for the country's prohibition on nuclear power to be lifted. But both critics and supporters see little future for large-scale nuclear power in Australia’s energy mix.
Upvote Downvote

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

11h - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN: Amazon.com, Inc Analysis and Research Report

12h - Asif

Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...

CUSIP: Q7419E358